Employees: 03 (2023.0)Legal category: 5785Size: PMECreation date: 2005-12-28 (20 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: TIGY (45510), Loiret
PHARMACIE DE TIGY : revenue, balance sheet and financial ratios
PHARMACIE DE TIGY is a French company
founded 20 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in TIGY (45510),
this company of category PME
shows in 2023 a revenue of 3.5 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DE TIGY (SIREN 480988617)
Indicator
2025
2024
2023
2022
2021
2020
2018
2017
Revenue
N/C
N/C
3 455 299 €
3 930 839 €
N/C
N/C
N/C
N/C
Net income
323 106 €
389 441 €
327 489 €
329 377 €
243 613 €
200 850 €
49 385 €
90 888 €
EBITDA
N/C
N/C
439 638 €
447 158 €
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
9.5%
8.4%
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE DE TIGY generates positive net income of 323 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 91 k€ -> 323 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
323 106 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 167%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 32%. The balance between equity and debt is satisfactory.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
167.493%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
31.549%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2020
2021
2022
2023
2024
2025
Debt ratio
177.793
133.008
76.641
481.372
247.09
153.68
93.355
167.493
Financial autonomy
30.716
34.14
47.011
15.406
23.599
33.343
43.059
31.549
Repayment capacity
None
None
None
None
3.914
3.509
None
None
Cash flow / Revenue
None%
None%
None%
None%
8.422%
9.666%
None%
None%
Sector positioning
Debt ratio
167.492025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Average
In 2025, the debt ratio of PHARMACIE DE TIGY (167.49) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
31.55%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Average-6 pts over 3 years
In 2025, the financial autonomy of PHARMACIE DE TIGY (31.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
3.51 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of PHARMACIE DE TIGY (3.51) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 271.13. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
271.134
Liquidity indicators evolution PHARMACIE DE TIGY
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2020
2021
2022
2023
2024
2025
Liquidity ratio
170.319
113.543
167.025
272.705
215.658
265.652
275.109
271.134
Interest coverage
None
None
None
None
0.458
0.299
None
None
Sector positioning
Liquidity ratio
271.132025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Excellent
In 2025, the liquidity ratio of PHARMACIE DE TIGY (271.13) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
0.3x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE DE TIGY (0.3x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DE TIGY
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
314 900 €
385 404 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
22
30
0
0
Customer payment term (days)
0
0
0
0
9
10
0
0
Supplier payment term (days)
0
0
0
0
37
39
0
0
Positioning of PHARMACIE DE TIGY in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE DE TIGY is estimated at
5 132 577 €
(range 3 482 991€ - 8 053 720€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
3482k€5132k€8053k€
5 132 577 €Range: 3 482 991€ - 8 053 720€
NAF 5 année 2025
Valuation method used
Net Income Multiple
323 106 €
×
15.9x
=5 132 577 €
Range: 3 482 991€ - 8 053 720€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DE TIGY with other companies in the same sector:
Frequently asked questions about PHARMACIE DE TIGY
What is the revenue of PHARMACIE DE TIGY ?
The revenue of PHARMACIE DE TIGY in 2023 is 3.5 M€.
Is PHARMACIE DE TIGY profitable?
Yes, PHARMACIE DE TIGY generated a net profit of 323 k€ in 2025.
Where is the headquarters of PHARMACIE DE TIGY ?
The headquarters of PHARMACIE DE TIGY is located in TIGY (45510), in the department Loiret.
Where to find the tax return of PHARMACIE DE TIGY ?
The tax return of PHARMACIE DE TIGY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DE TIGY operate?
PHARMACIE DE TIGY operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart